HC Wainwright Upgrades Vor Biopharma (NYSE:VOR) to "Buy"

HC Wainwright upgraded shares of Vor Biopharma (NYSE:VOR - Free Report) from a neutral rating to a buy rating in a research note issued to investors on Monday morning, MarketBeat.com reports. The brokerage currently has $3.00 target price on the stock. HC Wainwright also issued estimates for Vor Biopharma's Q2 2025 earnings at ($1.25) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.88) EPS, Q1 2026 earnings at ($0.18) EPS, Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.69) EPS, FY2027 earnings at ($0.65) EPS, FY2028 earnings at $0.05 EPS and FY2029 earnings at $0.24 EPS.

VOR has been the subject of a number of other research reports. Jones Trading cut shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. Oppenheimer reissued an "outperform" rating and set a $8.00 price objective on shares of Vor Biopharma in a research report on Friday, March 21st. JMP Securities restated a "market perform" rating and set a $6.00 target price on shares of Vor Biopharma in a research note on Friday, May 9th. Stifel Nicolaus lowered their target price on Vor Biopharma from $12.00 to $5.00 and set a "buy" rating on the stock in a report on Friday, March 21st. Finally, Baird R W lowered Vor Biopharma from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $5.63.

Vor Biopharma Stock Up 30.0%

Shares of NYSE:VOR traded up $0.44 during trading on Monday, reaching $1.89. The stock had a trading volume of 24,491,873 shares, compared to its average volume of 4,216,590. The stock has a fifty day simple moving average of $0.41 and a two-hundred day simple moving average of $0.84. Vor Biopharma has a 52 week low of $0.13 and a 52 week high of $2.04. The firm has a market capitalization of $235.55 million, a price-to-earnings ratio of -1.14 and a beta of -0.51.

Institutional Investors Weigh In On Vor Biopharma

A number of institutional investors have recently added to or reduced their stakes in VOR. Goldman Sachs Group Inc. raised its holdings in Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after acquiring an additional 58,247 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Vor Biopharma during the first quarter valued at approximately $140,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Vor Biopharma in the first quarter valued at $100,000. Money Concepts Capital Corp lifted its position in Vor Biopharma by 106.1% in the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock worth $37,000 after purchasing an additional 26,535 shares during the period. Finally, Two Sigma Investments LP lifted its position in Vor Biopharma by 18.9% in the fourth quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock worth $181,000 after purchasing an additional 25,930 shares during the period. 97.29% of the stock is owned by institutional investors and hedge funds.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.